Quadrant Capital Group’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-510
| Closed | -$11.5K | – | 2182 |
|
|
2026
Q1 | $11.5K | Sell |
510
-45
| -8% | -$1K | ﹤0.01% | 2157 |
|
|
2025
Q4 | $14.4K | Hold |
555
| – | – | ﹤0.01% | 2109 |
|
|
2025
Q3 | $14.3K | Buy |
+555
| New | +$13.6K | ﹤0.01% | 2056 |
|
|
2025
Q2 | – | Sell |
-6,710
| Closed | -$167K | – | 2232 |
|
|
2025
Q1 | $167K | Buy |
6,710
+6,155
| +1,109% | +$147K | 0.01% | 1377 |
|
|
2024
Q4 | $10.5K | Buy |
555
+86
| +18% | +$1.51K | ﹤0.01% | 2113 |
|
|
2024
Q3 | $7.06K | Sell |
469
-18
| -4% | -$308 | ﹤0.01% | 2237 |
|
|
2024
Q2 | $13.9K | Sell |
487
-839
| -63% | -$23.9K | ﹤0.01% | 2001 |
|
|
2024
Q1 | $38.7K | Sell |
1,326
-998
| -43% | -$30.7K | ﹤0.01% | 1529 |
|
|
2023
Q4 | $78.4K | Buy |
2,324
+885
| +62% | +$25.9K | 0.01% | 1136 |
|
|
2023
Q3 | $44.1K | Sell |
1,439
-55
| -4% | -$1.98K | ﹤0.01% | 1334 |
|
|
2023
Q2 | $59.9K | Sell |
1,494
-1,402
| -48% | -$58K | 0.01% | 1162 |
|
|
2023
Q1 | $118K | Buy |
2,896
+1,947
| +205% | +$77.5K | 0.01% | 743 |
|
|
2022
Q4 | $36.6K | Buy |
949
+74
| +8% | +$3.6K | ﹤0.01% | 1361 |
|
|
2022
Q3 | $47K | Buy |
875
+693
| +381% | +$38.5K | 0.01% | 1075 |
|
|
2022
Q2 | $11K | Buy |
182
+48
| +36% | +$3.14K | ﹤0.01% | 1620 |
|
|
2022
Q1 | $10K | Hold |
134
| – | – | ﹤0.01% | 1655 |
|
|
2021
Q4 | $8K | Sell |
134
-6
| -4% | -$331 | ﹤0.01% | 1729 |
|
|
2021
Q3 | $8K | Buy |
140
+6
| +4% | +$346 | ﹤0.01% | 1716 |
|
|
2021
Q2 | $8K | Hold |
134
| – | – | ﹤0.01% | 1680 |
|
|
2021
Q1 | $9K | Hold |
134
| – | – | ﹤0.01% | 1557 |
|
|
2020
Q4 | $8K | Hold |
134
| – | – | ﹤0.01% | 1507 |
|
|
2020
Q3 | $8K | Hold |
134
| – | – | ﹤0.01% | 1333 |
|
|
2020
Q2 | $7K | Buy |
134
+86
| +179% | +$3.59K | ﹤0.01% | 1510 |
|
|
2020
Q1 | $2K | Buy |
+48
| New | +$1.99K | ﹤0.01% | 1885 |
|
|
2019
Q3 | – | Sell |
-712
| Closed | -$30K | – | 2364 |
|
|
2019
Q2 | $30K | Buy |
+712
| New | +$30.2K | ﹤0.01% | 1453 |
|
|
2018
Q2 | – | Sell |
-111
| Closed | -$3K | – | 2190 |
|
|
2018
Q1 | $3K | Buy |
+111
| New | +$3.95K | ﹤0.01% | 1725 |
|
|
2016
Q2 | – | Sell |
-96
| Closed | -$5K | – | 2049 |
|
|
2016
Q1 | $5K | Buy |
96
+16
| +20% | +$936 | ﹤0.01% | 1170 |
|
|
2015
Q4 | $6K | Buy |
+80
| New | +$4.53K | ﹤0.01% | 998 |
|
Other funds holding PCRX
DPCM
Quadrant Capital Group's PCRX Position: Q2 2026 in Review
Quadrant Capital Group sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 510 shares — an estimated $11.5K sold.
Quadrant Capital Group first reported a position in PCRX in Q4 2015 and held it in 28 quarters. The position peaked at $167K in Q1 2025. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- Quadrant Capital Group reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
- Quadrant Capital Group sold 510 Pacira BioSciences shares in Q2 2026, an estimated $11.5K.
- Quadrant Capital Group first reported a position in Pacira BioSciences in Q4 2015 and held it in 28 quarters.
- Quadrant Capital Group's Pacira BioSciences position peaked at $167K in Q1 2025.
- 254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.